Notable notes from Australia Biotech Invest

About the author:

Author name:

By Scott Power

Job title:

Senior Analyst

Date posted:

29 October 2013, 7:20 AM

Sectors Covered:

Healthcare, Life Sciences

Here are my key takeaways from day one of the 2013 Australia Biotech Invest conference:

Allied Healthcare (AHZ)

I updated my Allied Healthcare (AHZ) research post the recent capital raising. The new price target is A$0.20 and the upgrade comes mainly from US market forecasts for CardioCel which I have now included given the recent success in securing European approval. The US FDA approval is expected 1HCY14. 

The company has done a great job on delivery on milestones.

Bionomics (BNO)

CEO Deborah Rathjen seems pretty confident the company can deliver on more partnering deals over the next two quarters. Given recent partnering success with Merck and their pain program, I would back her to deliver again. Partnering success will send the share price much higher.

Worth jumping on board.

IDT Limited (IDT)

CEO Paul MacLeman told the audience he expected the company to reach profitability in FY15. We think this will be well received by the market. 

I suggest getting ahead of the curve and buying this name.

Invion (IVX)

The presentation from CEO Greg Collier was a standout presentation. Key takeaways were interim results from the smoking cessation trial due late CY13 and a new program for an inhaled asthma product.

This is a well managed company with clear partnering opportunities on successful clinical results.

More information

If you are interested in finding out more about any of these companies, please contact your nearest Morgans office.

Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.